Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lonardi

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|April 7, 2011
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patientsE Bignotti, M Ragnoli, L Zanotti, et al.
The Pharmacogenomics Journal|October 22, 2014
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatinE Cecchin, G Perrone, S Nobili, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2019
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studiesJ Taieb, Q Shi, L Pederson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2025
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upR-D Hofheinz, E Fokas, L Benhaim, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|July 3, 2014
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesityB Spoto, E Di Betta, F Mattace-Raso, et al.
ESMO Open|October 1, 2025
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trialY Y Janjigian, A Kawazoe, J Xu, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 studyR Garcia-Carbonero, E Elez, P García-Alfonso, et al.
ESMO Open|October 2, 2024
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational studyF Tosi, L Salvatore, E Tamburini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|April 7, 2011
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patientsE Bignotti, M Ragnoli, L Zanotti, et al.
The Pharmacogenomics Journal|October 22, 2014
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatinE Cecchin, G Perrone, S Nobili, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2019
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studiesJ Taieb, Q Shi, L Pederson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2025
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upR-D Hofheinz, E Fokas, L Benhaim, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|July 3, 2014
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesityB Spoto, E Di Betta, F Mattace-Raso, et al.
ESMO Open|October 1, 2025
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trialY Y Janjigian, A Kawazoe, J Xu, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 studyR Garcia-Carbonero, E Elez, P García-Alfonso, et al.
ESMO Open|October 2, 2024
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational studyF Tosi, L Salvatore, E Tamburini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
Pageof 12